Recent Updates
Recently added Catalysts
STIM Positive Sentiment

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Key Takeaway: Neuronetics, Inc. announced the granting of inducement awards to a non-executive employee under NASDAQ Listing Rule 5635(c)(4). The awards were approved by the Compensation Committee and are part of the company's 2020 Inducement Incentive Plan. Neuronetics is known for its NeuroStar® TMS technology and operates a large network of interventional psychiatry clinics.

Market Sentiment Analysis

POSITIVE FACTORS

  • Neuronetics granted inducement awards to a non-executive employee.
  • The awards are part of the 2020 Inducement Incentive Plan.
  • Neuronetics is recognized for its innovative treatment technologies.

Full Press Release Details

MALVERN, Pa., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced the granting of inducement award(s) to one non-executive employee as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), this award was approved by Neuronetics’ Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient’s continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company’s 2020 Inducement Incentive Plan.

Restricted stock units (“RSUs”)

Name Number of Inducement Plan RSUs Vesting Schedule
Julia Roussel 9,000 1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date.
About Neuronetics Neuronetics, Inc. is a leader in interventional mental health, combining innovative treatment technologies with direct patient care. Through its NeuroStar® Advanced Therapy system, the company is a leading provider of transcranial magnetic stimulation (TMS) treatment and, through Greenbrook, operates one of the largest interventional psychiatry clinic networks in the United States, offering both TMS and SPRAVATO® therapies. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults and is backed by what we believe is the largest clinical data set of any TMS treatment system for depression. Greenbrook treatment centers also offer SPRAVATO® (esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (“TRD”) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with MDD with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1
The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com.
Neuronetics Contact: Investors: Mark Klausner or Aman Patel ICR Healthcare 443-213-0499 ir@neuronetics.com
Media: EvolveMKD 646.517.4220 NeuroStar@evolvemkd.com
References 1 The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®. For more important safety information about SPRAVATO®, please visit spravatohcp.com.

Frequently Asked Questions

What is the purpose of the inducement awards?

The inducement awards are granted as a material inducement for employment.

Who approved the inducement awards?

The awards were approved by Neuronetics' Compensation Committee.

What is the 2020 Inducement Incentive Plan?

It is the plan under which the inducement awards are granted.

What technologies does Neuronetics provide?

Neuronetics provides NeuroStar® TMS technology and SPRAVATO® therapies.

Last updated: Nov 18, 2026